Use of infliximab-daclizumab combination for the treatment of acute and chronic graft-versus-host disease of the liver and gut

Vilmarie Rodriguez, Peter M. Anderson, Barbara A. Trotz, Carola A.S. Arndt, Julia A. Allen, Shakila P. Khan

Research output: Contribution to journalArticle

23 Scopus citations

Abstract

Infliximab-daclizumab was used to treat acute and chronic liver and gut graft-versus-host disease (GVHD) in two children after standard immunosuppressive therapy failed. Infliximab (10 mg/kg weekly, 4 doses) and daclizumab (1 mg/kg, days 1, 4, 8, 15, and 22) were given over 1 month. In case 1, grade 2 chronic GVHD of the liver developed 1 year after transplantation and failed to improve with tacrolimus, mycophenolate mofetil, and prednisone. In case 2, corticosteroid-unresponsive grade 3 acute liver and gut GVHD developed on day +37. In both patients, GVHD responded to the infliximab-daclizumab regimen without toxicity and immunosuppressive therapy was discontinued.

Original languageEnglish (US)
Pages (from-to)212-215
Number of pages4
JournalPediatric Blood and Cancer
Volume49
Issue number2
DOIs
StatePublished - Aug 1 2007

Keywords

  • Daclizumab
  • Graft-versus-host disease
  • Immunosuppression
  • Infliximab

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Hematology
  • Oncology

Fingerprint Dive into the research topics of 'Use of infliximab-daclizumab combination for the treatment of acute and chronic graft-versus-host disease of the liver and gut'. Together they form a unique fingerprint.

  • Cite this